Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nanjing Ningdan New Drug Technology

Request full access

A company developing new drugs for central nervous system diseases

ChinaFounded 2020Biotech & Life Sciences

About Nanjing Ningdan New Drug Technology

Nanjing Ningdan New Drug Technology Co., Ltd., also known as Neurondawn, is a clinical-stage biopharmaceutical company established in December 2020. The company was founded by Chairman and CEO, Yang Shibao, and co-founder Chen Rong. Yang Shibao is noted as the inventor and project leader for the Class 1 new drug, Xianbixin®, and previously held the position of project director at Simcere Pharmaceutical, where he led the development of seven new drug varieties. Chen Rong holds a Ph.D. in Medicinal Chemistry from China Pharmaceutical University and has extensive experience in drug research and development.

The firm concentrates its efforts on developing novel drugs for central nervous system (CNS) diseases, aiming to provide effective solutions for patients with conditions like stroke, Alzheimer's disease, and depression. Neurondawn operates on a research and development-driven business model, focusing on the entire lifecycle of drug development from discovery to commercialization. Its revenue generation is anticipated from the successful development and subsequent marketing of its pipeline products, as well as potential partnerships and collaborations within the pharmaceutical industry. The company serves patients globally who are affected by CNS disorders.

Neurondawn possesses a comprehensive in-house research and development platform that covers drug chemistry synthesis, compound screening, CMC (Chemistry, Manufacturing, and Controls) development, and clinical research. The company has built a robust pipeline of CNS drug candidates. This includes a sublingual formulation of Xianbixin®, developed in collaboration with Simcere Pharmaceutical, which has been submitted for marketing approval and received a "Breakthrough Therapy Designation" from the U.S. FDA. The pipeline also features several other projects at various stages of clinical and preclinical research, such as Y-1 for Alzheimer's and brain tumors, Y-2 for stroke, and Y-3 for stroke and post-stroke depression. Neurondawn has established several key technology platforms, including the ND-S® sublingual formulation platform, the ND-M® multi-target drug development platform, and the ND-C® combination drug platform.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
17.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Nov 2024 $28M $110M Fujian Huaxing Venture Capital ↗
EARLY VCOther financing Nov 2023 $0 — Tencent ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Nanjing Ningdan New Drug Technology in its local ecosystem

Live from Dealroom

The Nanjing Ningdan New Drug Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Simcere Pharma
  • China Merchants Health
  • Tencent

Series B and later1 investor entered at this stage

  • Fujian Huaxing Venture Capital

Other known investors1 additional known investor

  • Nanjing Medical University
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nanjing Ningdan New Drug Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nanjing Ningdan New Drug Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.